SLC5A2 and type 2 diabetes mellitus: In this context, the primary objective of this study is to evaluate changes in albuminuria and renal function over 12 months of treatment with the original empagliflozin-linagliptin FDC in patients with T2DM who were previously uncontrolled on a DPP4-i regimen and were SGLT2-i-naïve.